MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1093/ejcts/ezaf103

Медицинская библиотека · European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery · 2025

Longitudinal outcomes following international multicentre experience with robotic aortic valve replacement†.

Wei Lawrence M, Pereda Daniel, Ramzy Danny, Khaliel Feras H, Murtaza Ghulam, Mehaffey James Hunter, Chi Nai-Hsin, Poffo Robinson, Černý Štěpán, Vojáček Jan, Yan Tristan D, Melnitchouk Serguei, Weber Alberto C, Smith Robert L, Raikar Goya V, Darehzereshki Ali, Geirsson Arnar, Arghami Arman, Navia Jose L, Bonatti Johannes, Badhwar Vinay

СтатьяМногоцентровое исследованиеПеревод в очереди

Аннотация

OBJECTIVES

In an effort to maintain the technical aspects of traditional prosthetic surgical aortic valve replacement (AVR) while reducing invasiveness and facilitate options for concomitant operations, transaxillary lateral mini-thoracotomy endoscopic robotic-assisted aortic valve replacement (RAVR) has been introduced. The present data highlight the contemporary international collaborative experience.

METHODS

All consecutive patients undergoing standardized RAVR across 10 international sites (1/2020-7/2024) were evaluated using a central database with 1 year follow-up.

RESULTS

A total of 300 patients were analysed with a median predicted risk of 1.6% with aortic stenosis in 85.7%, nearly half with bicuspid valves. Biological prostheses were implanted in 220 (73.3%) with a median valve size 23 mm, 10% receiving aortic root enlargement, with 17% of all patients undergoing concomitant procedures. Median cross-clamp 120 min with no conversions to sternotomy. Median length of stay was 5 days, 4.3% with prolonged ventilation, 1.7% renal failure, 1.0% stroke and 8.3% required re-thoracotomy for evacuation of haemothorax. There were two 30-day operative mortalities (0.7%). The new permanent pacemaker rate for the full cohort was 2.6%. Of 163 patients with complete 1-year clinical and echocardiographic follow-up, mean aortic valve gradient was 10 mmHg and all but 2 patients (1.2%) had trace to no prosthetic or paravalvular insufficiency.

CONCLUSIONS

RAVR is safe and effective, providing the reproducible benefits of surgical AVR while affording a less invasive approach that permits the opportunity for concomitant procedures. For low and intermediate risk patients with aortic valve disease, RAVR is a potential reproducible alternative for patients and heart teams.

Для цитирования: Wei Lawrence M, Pereda Daniel, Ramzy Danny, Khaliel Feras H, Murtaza Ghulam, Mehaffey James Hunter, Chi Nai-Hsin, Poffo Robinson, Černý Štěpán, Vojáček Jan, Yan Tristan D, Melnitchouk Serguei, Weber Alberto C, Smith Robert L, Raikar Goya V, Darehzereshki Ali, Geirsson Arnar, Arghami Arman, Navia Jose L, Bonatti Johannes, Badhwar Vinay. Longitudinal outcomes following international multicentre experience with robotic aortic valve replacement†.. European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery. 2025. DOI: 10.1093/ejcts/ezaf103.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.